Grannus Therapeutics, Inc. — Form D
Grannus Therapeutics, Inc. of INDIANAPOLIS, IN, a company, filed a Form D exempt-offering notice with the SEC on 2022-01-21. The offering totals $1.0M, of which $950K was reported sold. Industry: Biotechnology.
Offering
- Filed: 2022-01-21
- Form: D
- Accession: 0001905806-22-000001
- Industry: Biotechnology
- Exemptions: 06b
- Total offering: $1.0M
- Amount sold: $950K
- Remaining: $50K
- Minimum investment: $35K
- Investors: 11
- Date of first sale: 2022-01-12
- Security types: equity
- Revenue range: Decline to Disclose
- SEC file number: 021-430313
Issuer
- Name: Grannus Therapeutics, Inc.
- CIK: 0001905806
- Entity type: Corporation
- Jurisdiction: UNITED STATES
- Incorporated: 2020
- Address: 7210 N. PENNSYLVANIA STREET, INDIANAPOLIS, IN, 46240
- Phone: 3174146205
Officers, directors & promoters (4)
| Name | Role | Location |
|---|
| James Thompson | Director | Rushford, MN |
| John Foglesong | Director | Indianapolis, IN |
| John Foglesong | Executive Officer | Indianapolis, IN |
| Brian Blagg | Director | Indianapolis, IN |
Other filings by this issuer (1)
More